ClinicaliQ Trial Snapshot
- A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed — Recruiting • Phase III • Infectious Disease • NCT07650916.
- What is being tested: Cabotegravir ultra long-acting (CAB ULA) plus rilpivirine ultra-acting (RPV ULA) injections are being compared against standard long-acting formulations (CAB LA and RPV LA) to evaluate efficacy, safety, and tolerability in maintaining viral suppression.
- Patient eligibility overview: Adults and adolescents with HIV who are currently virologically suppressed (undetectable viral load) on existing antiretroviral therapy are eligible to participate in this study.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study compares the efficacy, safety and tolerability of CAB ULA and RPV ULA administered with CAB long acting (LA) and RPV LA administered in adults and adolescents with HIV who are virologically suppressed on anti-retroviral therapy (ART).
Eligibility Snapshot
- : Patient Study Participant (PSP) Inclusion criteria: * Adults and adolescents with HIV-1 infection aged 12 years or older with a weight >35 kg. * Documented HIV-1 RNA measurements
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.